Welcome to our dedicated page for ROCKET PHARMACEUTICALS SEC filings (Ticker: RCKTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKET PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKET PHARMACEUTICALS's regulatory disclosures and financial reporting.
Rocket Pharmaceuticals reported that director David P. Southwell received 150,000 restricted stock units on August 3, 2026 as compensation under a July 21, 2026 consulting agreement covering strategic and financial activities. The RSUs convert one-for-one into common stock and vest beginning August 3, 2027, with the balance vesting in equal quarterly installments over the following two years. After this award, Southwell holds 204,522 shares directly and 113,124 shares indirectly through The David P. Southwell Irrevocable Trust dated April 14, 2024.
Rocket Pharmaceuticals reported a positive clinical safety update from the initial three patients treated with RP-A501 under the modified protocol in its global, pivotal Phase 2 trial for Danon disease. The patients received a recalibrated dose of 3.8 × 10¹³ GC/kg plus an immunomodulatory regimen of rituximab, sirolimus, and corticosteroids, given sequentially with at least four weeks between infusions. To date, no thrombotic microangiopathy, capillary leak syndrome, or other significant safety concerns have been observed in these patients.
The pivotal Phase 2 study is designed as a 12-patient, single-arm trial. Rocket is actively engaging with the FDA to align on the path to dosing additional patients and completing the trial and expects an update on the regulatory pathway, as well as a comprehensive Danon disease program update, in the second half of 2026. RP-A501 is a single intravenous AAV9.LAMP2B gene therapy that has demonstrated safety and efficacy in clinical studies and holds multiple U.S. and EU regulatory designations, including RMAT, Fast Track, Rare Pediatric Disease, Orphan Drug, ATMP, and PRIME.
Vanguard Portfolio Management reports a passive ownership stake in Rocket Pharmaceuticals Inc common stock. Vanguard beneficially owns 5,847,541 shares, representing 5.35% of the class as of June 30, 2026. Vanguard has sole voting power over 37,508 shares and sole dispositive power over all 5,847,541 shares, with no shared voting or dispositive power. The stake aggregates securities held by Vanguard Portfolio Management LLC and certain affiliated entities and funds over which they exercise dispositive and/or voting power. Vanguard and related investment companies and accounts have the right to receive, or direct the receipt of, dividends and sale proceeds for these securities, and no other single person’s interest exceeds 5% of the class.
Rocket Pharmaceuticals, Inc. executive Joseph Manhede, the Principal Accounting Officer, filed an initial ownership report showing his equity position in the company. The filing reflects 52,576 shares of Common Stock held directly, represented by restricted stock units that convert to common shares on a one-for-one basis.
These RSUs were granted on May 4, 2026. One-third of the units will vest on May 4, 2027, with the remaining units vesting in equal quarterly installments over the following two years. The filing does not report any open-market purchases or sales, only the existing equity award and its vesting schedule.
ROCKET PHARMACEUTICALS, INC. director and 10% owner Roderick Wong received new equity awards in the form of common stock and options. He was granted 27,832 restricted stock units that convert into common shares on a one-for-one basis and vest in full on June 18, 2027. He also received a stock option for 78,960 shares of common stock at an exercise price of $3.35 per share, which becomes fully vested and exercisable on June 18, 2027 and expires on June 18, 2036. Following these awards, he holds 75,499 common shares directly and 18,188,457 shares indirectly through investment funds managed by RTW Investments, LP.
Rocket Pharmaceuticals director Peter Fong received equity awards as part of his compensation. He was granted 22,862 restricted stock units that convert into common stock on a one-for-one basis and will vest in full on June 18, 2027. He also received a stock option to purchase 64,860 shares of common stock at an exercise price of $3.35 per share, which will become fully vested and exercisable on June 18, 2027 and will expire on June 18, 2036. Following the restricted stock unit grant, his direct common stock holdings reported in this filing total 76,195 shares.
ROCKET PHARMACEUTICALS, INC. director Mikael Dolsten reported routine equity compensation awards rather than open-market trades. He received 22,862 restricted stock units that convert into common stock on a one-for-one basis and 64,860 stock options with an exercise price of $3.35 per share.
The RSUs and options both vest in full on June 18, 2027, with the options expiring on June 18, 2036. After the RSU grant, Dolsten directly holds 67,082 shares of common stock. The filing reflects compensation-related acquisitions, not purchases or sales in the market.
ROCKET PHARMACEUTICALS, INC. director Fady Ibraham Malik reported receiving equity awards tied to the company’s common stock. He was granted 22,862 restricted stock units that convert into common shares on a one-for-one basis and will vest in full on June 18, 2027.
He also received a stock option covering 64,860 shares of common stock at an exercise price of $3.35 per share, which will become fully vested and exercisable on June 18, 2027 and expires on June 18, 2036. Following the RSU grant, he directly holds 52,862 common shares.
ROCKET PHARMACEUTALS, INC. director David P. Southwell reported equity awards, not open-market trades. He received 22,862 restricted stock units (RSUs) that convert one-for-one into common stock and will vest in full on June 18, 2027. He was also granted a stock option for 64,860 shares of common stock at an exercise price of $3.35 per share, which becomes fully vested and exercisable on June 18, 2027 and expires on June 18, 2036. Following these awards, he directly owns 54,522 shares of common stock and indirectly holds 113,124 shares through The David P. Southwell Irrevocable Trust dated April 14, 2024.